BERLIN, Dec 03, 2009 (BUSINESS WIRE) -- At the KMIS meeting (Klinisch-Mikrobiologisch-Infektiologisches Symposium) on Dec. 3-5, 2009 in Berlin, Bruker Daltonics announces a framework agreement with Synlab (www.synlab.de) concerning molecular microbial identification based on MALDI-TOF mass spectrometry. Synlab is a European private diagnostic laboratory association, and Bruker Daltonics is the worldwide leading provider of mass spectrometry-based microorganism identification solutions. Synlab currently has more than 70 diagnostic laboratories in Germany and other European countries.
Synlab and Bruker have concluded a long-term partnership agreement in order to equip the laboratories of the Synlab association exclusively with theMALDI BIOTYPERsystem for fast and reliable molecular microbial identification. TheMALDI BIOTYPERis currently already in routine use in Synlab's clinical microbiology centers in Trier, Weiden and Dachau in Germany. Moreover, Bruker and Synlab intend to further enlarge and refine theMALDI BIOTYPERreference library using well defined clinical isolates from the daily microbiology routine work of the Synlab laboratories.
这MALDI BIOTYPER被整合到Synlab实验室的微生物学工作流程中，将快速分子鉴定与常规抗生素易感性测试（AST）结合在一起。这MALDI BIOTYPERreports the identification results into the existing laboratory information systems (LIS). Integration with LIS MCS (http://www.mcs-ag.com），Medat（http://www.medat.de) and Vision4health (http://www.vision4health.com) has already been established for Synlab, while integration with other LIS providers is also possible.
Dr. Ulrich Knipp, Technical Head of Microbiology at Synlab in Trier, commented: "After evaluating theMALDI BIOTYPERvery thoroughly within the Synlab group, we are convinced that Bruker Daltonics is the most reliable partner for microbial identification based on mass spectrometry, and is providing outstanding microbiological service and support. Bruker Daltonics is fully established in the clinical microbiology market, and theMALDI BIOTYPERfulfils our requirements for reliability and robustness. TheMALDI BIOTYPERrepresents a clear milestone substantiating our high quality molecular microbiology diagnostics."
Dr. Guido Mix, Director of Microbiology at Bruker Daltonics, added: "We are very pleased that ourMALDI BIOTYPERfulfils the high demands of leading clinical laboratories like Synlab. Our framework contract with Synlab validates our efforts to provide comprehensive service and applications support to our customers by our dedicated microbiologists, fully developed technicians network and dedicated IT specialists for integration into various laboratory information systems (LIS)."
About the BrukerMALDI BIOTYPER
Bruker's dedicatedMALDI BIOTYPERsolution (http://www.bdal.com) enables molecular identification, and taxonomical classification or dereplication of microorganisms like bacteria, yeasts and fungi. Classification and identification of microorganisms is achieved reliably and quickly using proteomic fingerprinting by high-throughput MALDI-TOF mass spectrometry. Applications include clinical routine microbial identification, environmental and pharmaceutical analysis, taxonomical research, food and consumer product safety and quality control, as well as marine microbiology. Bruker's robust MALDI Biotyper method requires minimal sample preparation efforts and offers low consumables cost per sample. TheMALDI BIOTYPER可在某些欧洲国家/地区根据欧盟指令EC/98/79在IVD-CE版本中提供，并在IVD-CE版本中获得。
ABOUT BRUKER CORPORATION (NASDAQ: BRKR)
布鲁克（Bruker）是分子和材料研究以及工业和应用分析的高性能科学工具和解决方案的领先提供商。必威东盟体育必威手机客户端了解更多信息：//www.fatactor.com
CAUTIONARY STATEMENT
本演讲中包含的任何陈述不描述历史事实的任何陈述都可能构成前瞻性陈述，因为该术语是在1995年的《私人证券诉讼改革法》中定义的。风险和不确定性可能导致实际结果与预期的结果有重大差异，包括但不限于与全球经济条件不利变化以及资本市场中的不利变化有关的风险和不确定性，我们已经获得或已获得的企业一体化将来可能会收购我们的产品的技术，产品开发和市场接受，产品的成本和价格，制造，竞争，依赖协作合作伙伴和主要供应商，资本支出和政府资助政策，政府法规的变化，实现经济刺激计划的预期收益S，知识产权权利，诉讼和对外币波动的暴露以及我们向美国证券交易委员会提交的文件中不时讨论的其他风险因素。这些因素和其他因素在我们向SEC的文件中进行了更详细的详细介绍，包括但不限于我们在附表14a上的最新代理声明，即我们的年度报告，即截至2008年12月31日的年度10-K年度报告，我们最多的年度最新的关于表格10-Q的季度报告以及我们目前关于8-K表格的报告。除法律要求外，我们明确违反了更新这些前瞻性陈述的任何意图或义务。>
Photos/Multimedia Gallery Available:http://www.businesswire.com
SOURCE: Bruker Daltonics
Karin Hoffmann, +49-421-2205-2041
MALDI BIOTYPERMarketing, Bruker Daltonics
kho@bdal.de